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MitophagyHuntington's disease (HD) is an inherited neurodegenerative disorder caused by polyglutamine expansion mu-
tations in the huntingtin protein. Despite its ubiquitous distribution, expression of mutant huntingtin (mHtt) is
particularly detrimental to medium spiny neurons within the striatum. Mitochondrial dysfunction has been as-
sociated with HD pathogenesis. Here we review the current evidence for mHtt-induced abnormalities in mito-
chondrial dynamics and quality control, with a particular focus on brain and neuronal data pertaining to
striatal vulnerability. We address mHtt effects on mitochondrial biogenesis, protein import, complex assembly,
fission and fusion, mitochondrial transport, and on the degradation of damaged mitochondria via autophagy
(mitophagy). For an integrated perspective on potentially converging pathogenic mechanisms, we also address
impaired autophagosomal transport and abnormal mHtt proteostasis in HD.
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Huntington's disease (HD) is a dominantly inherited neurodegener-
ative disease characterized by motor dysfunction, cognitive decline and
psychiatric disturbances (Ross and Tabrizi, 2011). HD is caused by CAG-regulated autophagy 1; Atg, autopha
t-binding; DIC, dynein intermediate
) receptor-associated protein like 1;
cells; Mff, mitochondrial fission facto
nuclear DNA ratio; MSNs, medium sp
, peroxisome proliferator-activated r
iatum; TAF4, TBP (TATA box binding
rkB, tyrosine receptor kinase B.
es, Faculty of Pharmacy, University of
ect.com).trinucleotide repeat expansion mutations that encode abnormally large
polyglutamine (polyQ) stretches at the N-terminal of the huntingtin
(Htt) protein (HDCRG, 1993). Mutations between 36 and 40 polyQ
have incomplete penetrance, whereas mutations beyond 41 polyQ are
fully penetrant (Walker, 2007). Individuals express mutant Htt (mHtt)gy-related protein; BDNF, brain-derived neurotrophic factor; BNIP3, BCL2/adenovirus E1B
chain; Drp1, dynamin-related protein 1; FEZ1, fasciculation and elongation protein zeta-1;
HAP1, huntingtin-associated protein 1; HDAC, Histone deacetylase; HD, Huntington’s dis-
r; Mfn, mitofusin; mHtt, mutant huntingtin; MiD, mitochondrial dynamics protein; Miro,
iny neurons; NIX (BNIP3L), BNIP3-like; NMDAR, NMDA receptor; NRF, nuclear respiratory
eceptor; PGC-1α, PPAR γ coactivator 1α; PINK1, PTEN-induced putative kinase 1; RanBP2,
protein)-associated factor 4; TIM, translocase of the inner membrane; TOM, translocase of
Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal.
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decade of life, the age of onset is inversely correlated with the polyQ ex-
pansion size, and very large expansions may cause juvenile or even in-
fantile HD (Ross and Tabrizi, 2011; Seneca et al., 2004). Significantly,
despite ubiquitous expression of mHtt in the brain and peripheral tis-
sues, preferential atrophy of the striatum is observed even prior to
onset of the manifestations of disease (Aylward et al., 2011; Paulsen
et al., 2010). Striatal atrophy stems from the degeneration of GABAergic
medium spiny neurons (MSNs), which normally constitute approxi-
mately 95% of the striatal neuronal population (Ehrlich, 2012). The
basis for the selective vulnerability of the striatalMSNs tomHtt remains
an outstanding question in the field.
Severalmechanisms have been proposed to contribute to HD patho-
genesis, involving gain of toxic function in mHtt together with loss of
normal Htt function (Zuccato et al., 2010), and leading to transcriptional
dysregulation (Francelle et al., 2014), synaptic dysfunction and
excitotoxicity (Plotkin et al., 2015; Sepers et al., 2014), differential
mHtt proteostasis (Margulis et al., 2014), defects in intracellular trans-
port (Hinckelmann et al., 2013), and mitochondrial dysfunction (Costa
et al., 2012; Oliveira, 2010a; Reddy et al., 2012).
Neurons are particularly vulnerable to mitochondrial dysfunction
given their energetic dependence on oxidative phosphorylation
(Bolanos et al., 2010; Oliveira, 2011), their polarized morphology
which requires efficient mitochondrial distribution to provide ATP
and calcium buffering to distant synapses (Leitão-Rocha et al., 2015;
Schwarz, 2013), and their postmitotic nature that demands effective
mitochondrial quality control mechanisms (Amadoro et al., 2014).
Mitochondria differ across tissues, cell-types and even sub-cellular com-
partments within neurons (Dubinsky, 2009; Kuznetsov et al., 2009). In-
deed, inherent differences inmitochondrial function, or in susceptibility
to mitochondrial dysfunction, are proposed to mediate the differential
neuronal vulnerability in several neurodegenerative disorders, includ-
ing HD (Brustovetsky et al., 2003; Dubinsky, 2009; Oliveira et al.,
2009; Pickrell et al., 2011).
Here we review the current evidence for disturbed mitochondrial
dynamics in HD, with a particular focus on brain and neuronal data
pertaining to striatal vulnerability. We use the term mitochondrial
dynamics to comprise several processes from the mitochondrial life
cycle that mediate mitochondrial generation (biogenesis), adoption of
morphology and size (fission-fusion), transport, and degradation. We
addressmitochondrial dynamics togetherwith the subject ofmitochon-
drial quality control since these dynamics are embedded in the path-
ways that segregate or recognize damaged mitochondria, and assist
their autophagic clearance (mitophagy) (Ni et al., 2015). For a broader
perspective, the discussion of biogenesis will include changes in mito-
chondrial protein import and complex assembly, whereas quality con-
trol will be complemented with data on autophagosomal transport
and mHtt proteostasis in HD.2. Mitochondrial biogenesis
Mitochondrial biogenesis requires a tight coordination between the
nuclear, cytosolic andmitochondrial compartments, since only aminor-
ity (13 proteins) of the full mammalianmitochondrial proteome (about
1100 to 1500 proteins) is locally encoded in the mitochondrial DNA
(mtDNA; Meisinger et al., 2008; Pagliarini et al., 2008). The transcrip-
tional co-activator PGC-1α is considered the master regulator of the
mitochondrial biogenesis program, acting in concert with nuclear respi-
ratory factors NRF1 and NRF2 (Scarpulla, 2011). Proteins translated in
the cytosol may be targeted to mitochondria via positively charged N-
terminal presequences recognized by the translocase of the outermem-
brane (TOM), and then transferred to the translocase of the innermem-
brane (TIM23) in a membrane potential-dependent manner (Schmidt
et al., 2010). Proteins within the TIM23 complex may fully translocate
to the mitochondrial matrix or insert into the inner membrane, wheresome will integrate into respiratory complexes (Harbauer et al., 2014;
Schulz et al., 2015).
Impaired PGC-1α signaling and defective mitochondrial biogenesis
were implicated in the mechanisms of striatal vulnerability in HD fol-
lowing data from PGC-1α knockout mice. These PGC-1α−/−mice ex-
hibited behavioral changes consistent with neurodegeneration,
presenting spongiform lesions primarily in the striatum and, less prom-
inently, in the motor cortex and hippocampus (Lin et al., 2004). More
recently, PGC-1α suppression in cultured neuronswas found to contrib-
ute to mHtt-induced increases in extrasynaptic NMDAR activity and
vulnerability to excitotoxic insults (Puddifoot et al., 2012). In wild-
type mice, PGC-1αmRNA levels were identical in striatum and cortex,
but mitochondrial/nuclear DNA ratios (mtDNA/nDNA) and citrate syn-
thase activity were higher in the striatum (Hering et al., 2015; Pickrell
et al., 2011). Interestingly, in R6/2 HD mice, PGC-1α mRNA levels
were similarly decreased in the striatum and cortex; however, only
the striatum presented decreased mtDNA/nDNA (Hering et al., 2015),
suggesting that the striatummay be particularly susceptible to reduced
PGC-1α expression.
In early-stage HD patients, PGC-1αmRNA levels were decreased in
the striatum (caudate nucleus), but not in the hippocampus or cerebel-
lum (Cui et al., 2006;Weydt et al., 2006).Within the striatum, data from
CAG140 knock-in mice showed that PGC-1α mRNA levels were de-
creased in MSNs and increased in cholinergic interneurons, which are
mostly spared in HD (Cui et al., 2006). Themechanism bywhich striatal
PGC-1α transcription is differently affected inMSNs and interneurons is
unknown. Nevertheless, mHtt is thought to repress PGC-1α transcrip-
tion by associating with the promoter region and interfering with the
activation functions of the transcription factors CREB and TAF4 (Cui
et al., 2006) (Fig. 1A).
It was recently reported thatmHtt inhibits protein import intomito-
chondria in vitro (isolatedmouse forebrainmitochondria and HdhQ111
striatal cell line) and in vivo (R6/2mice) (Jonas, 2014; Yano et al., 2014).
Using immunoprecipitation and TIM23 overexpression experiments,
the authors suggest that mitochondrial protein import is inhibited by
the direct interaction of mHtt with the TIM23 complex (Yano et al.,
2014) (Fig. 1B). Although the association between mHtt and mito-
chondria has been previously reported (reviewed in Oliveira, 2010b),
its sub-mitochondrial localization remains unsettled. Indeed, full-
length mHtt was found associated with the mitochondrial outer mem-
brane in HdhQ111 cells (Choo et al., 2004), whereas N-terminal mHtt
in R6/2micewas found associatedwith the surface of themitochondrial
membrane, but also clustered within degenerating mitochondria (Yu
et al., 2003). As the direct interaction between mHtt and TIM23 was re-
ported for bothHdhQ111 cells and R6/2mice (Yano et al., 2014), this re-
cent data suggests that both full-length and N-terminal mHtt are
associated with the mitochondrial inner membrane. Moreover, since
the deficit in protein import was more pronounced in synaptosomal
versus non-synaptosomal or liver mitochondria, and was present in
pre-symptomatic R6/2 mice without significant changes in mitochon-
drial respiratory control, the authors hypothesize that import impair-
ment might be an early abnormality intrinsic to neurons (Yano et al.,
2014). It would thus be interesting to assess whether this import defect
might be particularly pronounced or detrimental to striatal MSNs.
In addition to protein import, TIM23 assists the assembly of respira-
tory complexes (Mick et al., 2012), thus opening the possibility that
mHtt-TIM23 interactions would disturb such assembly. It is presently
unclearwhether defective complex assembly contributes forHDpathol-
ogy. Indeed, whereas one study reported defective complex II assembly
and activity in striatalmitochondria frommice injectedwithN-terminal
mHtt (Damiano et al., 2013), another study reported normal assembly
and activity of respiratory complexes in striatal and cortical mitochon-
dria fromR6/2mice (Hering et al., 2015). Nevertheless, other lines of ev-
idence suggest that the direct interaction between mHtt and neuronal
mitochondria is a relevant component of HD pathology, contributing
to calcium handling defects (Panov et al., 2002), disrupted
Fig. 1. Impairedmitochondrial biogenesis andprotein import inHD.A, Mutant Htt (mHtt) interferencewith the activation functions of the transcription factors CREB and TAF4may reduce
PGC-1α transcription (Cui et al., 2006). B, An interaction between mHtt and the TIM23 complex may impair mitochondrial protein import in HD (Yano et al., 2014).
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fission (Song et al., 2011).
3. Mitochondrial fission and fusion
Fission and fusion events modulate mitochondrial morphology,
number and size. Fission allows isolation of defective mitochondria,
partition during mitosis, and distribution along neuronal processes
(Otera et al., 2011). Drp1, a GTPase, is the main mediator of mitochon-
drial fission, forming constricting spirals that split both outer and
inner mitochondrial membranes (Smirnova et al., 2001); whereas
Fis1, Mff, MiD49 and MiD51 are key effector proteins that mediate
Drp1 recruitment and assembly on the outer membrane of mammalian
mitochondria (DuBoff et al., 2013). Fusion allows functional comple-
mentation, mixing mtDNA, RNA, proteins and lipids between mito-
chondria (Youle and van der Bliek, 2012). Mitofusins Mfn1 and Mfn2
mediate the fusion of mitochondrial outer membranes, whereas OPA1
mediates the fusion of inner membranes (Mishra and Chan, 2014).
In HD, evidence suggests thatmitochondrial dynamics is unbalanced
towards fission (Costa et al., 2010; Oliveira and Lightowlers, 2010). Ad-
vanced stageHDpatients exhibited elevatedmRNA andprotein levels of
the fission-associated Drp1 and Fis1, together with decreased levels of
mitofusins in striatal and cortical regions (Kim et al., 2010; Shirendeb
et al., 2011). Similarly, the cortex of BACHD mice also exhibited in-
creased mRNA levels of Drp1 and Fis1, together with decreased levels
for Mfn1 and Mfn2; being consistent with the increased mitochondrial
fragmentation found in cultured cortical neurons from these HD mice
(Shirendeb et al., 2012). The mechanisms by which mHtt alters the ex-
pression of mitochondrial fission-fusion genes remain uncertain.
Mitochondria in striatal neurons may be particularly prone to mHtt-
induced fragmentation given that they show an intrinsically higher
balance towards fission than cortical mitochondria (Guedes-Dias et al.,
2015). Moreover, mHtt may promote mitochondrial fission via direct
interaction with Drp1 (Song et al., 2011) or by promoting post-Fig. 2. Excessive mitochondrial fission in HD. Mutant Htt (mHtt)-induced decreases in the expr
2011; Shirendeb et al., 2012; Song et al., 2011); and increased nitric oxide (NO) leading to Drp
et al., 2013).translational modifications that enhance Drp1 activity (Chang and
Blackstone, 2010), as addressed below and illustrated in Fig. 2.
Increased levels of S-nitrosylated Drp1 were found in the brain of
HD patients, and also in the striatum but not in the cerebellum of
BACHD mice (Haun et al., 2013). S-nitrosylation of Drp1 was reported
to enhance its GTPase activity (Cho et al., 2009), whereas expression
of S-nitrosylation-resistant Drp1 prevented mitochondrial fragmenta-
tion in neurons expressing mHtt (Haun et al., 2013). Mechanistically,
mHtt expression increases neuronal nitric oxide (NO) production and
is more extensively nitrosylated than wild-type Htt, leading to the hy-
pothesis that mHtt-Drp1 interaction facilitates the transfer of NO to
Drp1, thereby enhancing mitochondrial fragmentation in HD (Haun
et al., 2013).
The affinity of mHtt for Drp1 is higher than that of wild-type Htt,
as judged from immunoprecipitation experiments with brain ho-
mogenates from HD patients and mouse models (Song et al., 2011).
The interaction of mHtt with Drp1 increased its GTPase activity
in vitro, suggesting that this interaction could promote mitochondrial
fragmentation in HD (Song et al., 2011). In agreementwith this hypoth-
esis, Drp1 GTPase activity was increased in the cortex of HD patients,
and also in the striatum and cortex of BACHD mice (Shirendeb et al.,
2012). Significantly, upregulation of Drp1 GTPase activity was stronger
in the striatum than in the cortex of BACHD mice (Shirendeb et al.,
2012).
P110 is a peptide designed to blockDrp1 interactionwith Fis1 and so
to inhibit mitochondrial fission (Qi et al., 2013). Treatment of HdhQ111
cells and MSNs (derived from HD iPS cells) with P110 reduced mito-
chondrial fragmentation and superoxide formation, and increasedmito-
chondrial membrane potential (Guo et al., 2013). Furthermore,
treatment with P110 suppressed striatal neuronal loss, improved
motor activity and reduced mortality in R6/2 HD mice (Guo et al.,
2013), suggesting that improvingmitochondrial dynamics and bioener-
getics may have a beneficial effect on the disease progression. In this
context, pharmacological inhibition of the tubulin deacetylase HDAC6ession of mitofusins (Mfn1/2); upregulation of Drp1 expression/activity (Shirendeb et al.,
1 S-nitrosylation (Drp1-SNO) may promote excessive mitochondrial fission in HD (Haun
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striatal neurons, reducing their intrinsic mitochondrial fragmentation
and approximating their fission-fusion balance to that of the less HD-
vulnerable cortical neurons (Guedes-Dias et al., 2015). Further studies
are thus warranted to assess the impact of HDAC6 inhibition on themi-
tochondrial dynamics of HD neurons.
4. Mitochondrial and vesicle transport
Transport along microtubules is mainly mediated by two superfam-
ilies of opposing motors: kinesins and dyneins. The kinesin-1/KIF5 fam-
ily is the main mediator of mitochondrial anterograde transport and, in
mammals, binds mitochondria through syntabulin, FEZ1, RanBP2
(MacAskill and Kittler, 2010), or the Miro/TRAK1 adaptor complex
(van Spronsen et al., 2013). Dynein mediates retrograde mitochondrial
transport, forming a complex with dynactin that binds mitochondria
through Miro and TRAK1 or TRAK2 (van Spronsen et al., 2013).
Mitochondrial transport was impaired in neurons expressing mHtt
(Chang et al., 2006; Orr et al., 2008; Trushina et al., 2004), however,
the mechanisms remain uncertain. Large mHtt aggregates may block
axoplasmic flow, aggregates may sequester motor proteins, and diffuse
mHtt may disrupt the trafficking complexes and their binding to mito-
chondria or microtubules (Oliveira, 2010b; Orr et al., 2008). Sig-
nificantly, mitochondrial transport in cortical neurons was disrupted
specifically at sites of mHtt aggregates (Chang et al., 2006), whereas in
striatal neurons, impairment occurred beforemHtt aggregate formation
(Orr et al., 2008). Thus, striatal neurons may be particularly vulnerable
to trafficking impairment by diffuse mHtt.
In addition to mitochondria, mHtt impairs the fast axonal transport
of vesicles, such as those containing BDNF, more severely in striatal
than in cortical neurons (Her and Goldstein, 2008). The neurotro-
phin BDNF is transported in vesicles along cortical axons projecting
to the striatum, using the kinesin-1 motor and the Htt/Htt-associated
protein 1 (HAP1) scaffolding complex (Gauthier et al., 2004). HAP1
may also mediate the transport of BDNF receptor TrkB in neurons
(Xiang et al., 2014), and TrkB transport was found impaired in striatal
neurons expressing mHtt (Liot et al., 2013). Impaired BDNF signaling
has been thought to contribute for selective striatal vulnerability in
HD (Gauthier et al., 2004; Zuccato and Cattaneo, 2007), and recent evi-
dence suggest that a defective postsynaptic response to BDNF due to re-
duced TrkB transport and availability may be a more prominent cause
for impaired BDNF signaling in HD than disturbed BDNF delivery to
the striatum (Liot et al., 2013; Plotkin et al., 2014).
The polyQ expansion in mHtt may also impair autophagosomal
transport (Wong and Holzbaur, 2014). Neuronal autophagosomes
are generated distally and display robust retrograde movement along
the axon towards the soma, where most cargo degradation likely
takes place (Lee et al., 2011; Maday and Holzbaur, 2014; Maday et al.,Fig. 3. Impairedmitophagy and autophagosomal transport inHD. A,Mutant Htt (mHtt)-mediate
tors (p62 or BNIP3/NIX) may compromise the recognition of ubiquitinated (ub) mitochondria b
Rui et al., 2015). B, Wild-type Htt and Htt-associated protein 1 (HAP1) form a scaffolding co
autophagosomal transport. Impairment of this retrograde transport by mHtt may limit autoph
tochondria (Wong and Hozlbaur, 2014).2012). Dynein and kinesin motors are both present in autophagosomes
(Maday et al., 2012), however, regulation by scaffolding complexes
limits kinesin processivity to sustain the dynein-mediated retrograde
transport (Fu et al., 2014). Recent evidence suggests that Htt and
HAP1 form a scaffolding complex in a subpopulation of LC3-positive
neuronal autophagosomes that enhances their dynein-dynactin-
driven transport towards the soma (Wong and Holzbaur, 2014). The
polyQ expansion in mHtt enhances its affinity for HAP1 (Li et al.,
1995). mHtt may thus disrupt the normal Htt-HAP1 association,
impairing autophagosomal transport and limiting the clearance of
cargo, such as damaged mitochondria (Wong and Holzbaur, 2014)
(Fig. 3).
Htt and mHtt show preferential association with the neuron-
specific dynein subunit DIC1A, versus the ubiquitous DIC2C (Wong
and Holzbaur, 2014). Although potentially contributing for neuron-
selective pathology, it seems unlikely that the mHtt-DIC1A association
determines striatal vulnerability as DIC1A is expressed in multiple
brain regions (Kuta et al., 2010). Nevertheless, since the Htt-HAP1 scaf-
folding complex seems confined to a subpopulation of autophagosomes
(Wong andHolzbaur, 2014), it would be interesting to addresswhether
such subpopulation is enriched in the HD vulnerable striatal MSNs, and
also if it has a prominent role in transporting defective mitochondria or
mHtt for autophagic degradation.
5. Mitophagy and huntingtin proteostasis
The clearance of defective mitochondria has been proposed to rely
on the activity of the PINK1/Parkin mitophagy pathway (Pickrell and
Youle, 2015). PINK1 accumulates in the outermembrane of depolarized
mitochondria, and recruits the E3-ubiquitin ligase Parkin (Burté et al.,
2015). Parkin-dependent ubiquitination promotes the degradation of
Miro and Mfn1/2, respectively, arresting the movement and fusion of
damaged mitochondria (Ashrafi and Schwarz, 2015; Birsa et al., 2014;
Tanaka et al., 2010; Wang et al., 2011). Autophagy receptors such as
optineurin or p62 may then link ubiquitinated mitochondria to
autophagosomal LC3, thereby mediating engulfment for mitophagic di-
gestion after autophagosome-lysosome fusion (Martinez-Vicente et al.,
2010; Rui et al., 2015; Wong and Holzbaur, 2014) (Fig. 3).
Several studies suggest that the removal of defective mitochondria
may be compromised inHD. Impairedmitophagywas recently reported
in flies expressing neuronal Htt-ex1p-Q93 and in HdhQ111 striatal cells
lines, being associated with decreased targeting of ubiquitinated mito-
chondria to autophagosomes (Khalil et al., 2015). The same study re-
ported that PINK1 overexpression was neuroprotective in flies and
restored mitophagy in HdhQ111 cells, and the proposed mechanism
was that PINK1 overexpressionmight lower the threshold of mitochon-
drial damage that must be crossed before mitophagy occurs (Khalil
et al., 2015).d disruption of the normal interactions between C-terminal Htt and the autophagic recep-
y LC3-containing isolationmembranes (Martinez-Vicente et al., 2010; Ochaba et al., 2014;
mplex that limits kinesin processivity and sustains dynein-dynactin-driven retrograde
agosome-lysosome fusion and the degradation of cargo such as mHtt or dysfunctional mi-
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is compromised in HD has been previously suggested following
data from non-neuronal models, and was proposed to stem from an
abnormal interaction between mHtt and the autophagy receptor p62
(Martinez-Vicente et al., 2010). Data from neuronal HDmodels, howev-
er, failed to identify impaired mitochondrial loading, but rather pointed
to the accumulation of undigested mitochondria due to disturbances in
the autophagosomal transport, which is required for efficient fusion
with lysosomes (Wong and Holzbaur, 2014) (Fig. 3).
Wild-type Htt has been proposed to play a physiological role
in mitophagy, either by its interaction with autophagy receptors or
due to its similarity with autophagy-related proteins. Specifically,
the Htt C-terminal was reported to interact with p62 to facilitate p62-
mediated cargo recognition, and this was considered relevant for
mitophagy since Htt-deficient cells presented lower mitophagy levels
(Rui et al., 2015). Further, the Htt C-terminal domain exhibits strong
similarities with the yeast autophagy-related protein 11 (Atg11)
(Ochaba et al., 2014). Since mitophagy in yeast involves the interaction
between cytosolic Atg11 and mitochondrial Atg32 (Kanki et al., 2015),
and since the Htt C-terminal can interact with mammalian Atg32
homologues (BNIP3 and NIX), mammalian mitophagy is proposed
to involve Htt-BNIP3/NIX interactions (Ochaba et al., 2014). Sig-
nificantly, BNIP3 and NIX also interact with autophagosomal LC3,
and while the BNIP3/NIX-associated mitophagy pathway has been
primarily associated with reticulocyte maturation (Ney, 2015), recent
evidence implicates this pathway in neuronal mitophagy (Shi et al.,
2014). Thus, wild-type Htt may have a role in mitophagy that is dis-
turbed by mHtt, nevertheless, whether and how N-terminal polyQ dis-
turbs the interaction of the C-terminal with mitochondria remains
undetermined.
In addition to changes in mitophagy, differences in mHtt proteo-
stasis may also play a role in HD pathogenesis, namely by influencing
the levels of toxicmHtt species (Margulis and Finkbeiner, 2014). Indeed,
evidence suggests that differential mHtt proteostasis, namely the mHtt
lifetime and mHtt aggregate formation, condition neuronal survival.
Specifically, diffuse mHtt mean lifetime directly correlates with neuro-
nal death and is higher in striatal than in cortical or cerebellar neurons
(Tsvetkov et al., 2013).Moreover, striatal neurons form lessmHtt aggre-
gates than cortical neurons (Guedes-Dias et al., 2015; Gutekunst et al.,
1999), and the survival of neurons without aggregates is inversely
proportional to their levels of diffuse mHtt (Arrasate et al., 2004). High
expression of the Rhes protein in the striatum supports increased
mHtt lifetime in this region: Rhes binds to mHtt and promotes its
sumoylation, which increases the levels of soluble mHtt and reduces
mHtt ubiquitination and aggregation (Subramaniamet al., 2009).More-
over, studies in PC12 cells indicate that Rhes binds Beclin-1 and acti-
vates autophagy, and that this Rhes-induced autophagic activation is
blocked by mHtt co-expression (Mealer et al., 2014). The mechanisms
behind differential mHtt proteostasis in striatal and cortical neurons
may thus involve differences in autophagy, being relevant that striatal
neurons with higher autophagic flux (lower LC3 mean lifetime) were
found to survive longer in the presence of mHtt (Tsvetkov et al., 2013).
Although we found no published studies that directly compare au-
tophagic flux in cortical versus striatal neurons expressing mHtt (but
see Baldo et al., 2013), data from wild-type neurons suggest that there
are differences in autophagy in these neuronal populations. Indeed,
lower autophagic flux (lower p62 accumulation after autophagy inhibi-
tionwith bafilomycin)was detected inwild-type striatal versus cortical
neurons (Guedes-Dias et al., 2015). Moreover, levels of the autophagic
protein GABARAPL1 (mammalian homologue of yeast Atg8) were
lower in the striatum compared to the cortex of the adult mouse brain
(Le Grand et al., 2013). Furthermore, levels of Ambra1 (activating mol-
ecule in Beclin1-regulated autophagy; Fimia et al., 2007) were lower in
MSNs when compared with interneurons from the adult mouse
striatum (Sepe et al., 2014). Taken together with evidence that the
‘mitophagy capacity’ (proportion of mitochondria in autophagosomes)was also lower in the wild-type mouse striatum versus cortex
(Diedrich et al., 2011), these data support the hypothesis that striatal
vulnerability inHDmay involve an intrinsically lower autophagic degra-
dation capacity, whichmight limit the efficient degradation ofmHtt and
dysfunctional mitochondria.
Pharmacological induction of autophagy is thus a potential strategy
to reduce mHtt lifetime and striatal vulnerability. Treatment with the
autophagy inducer 10-NCPdecreased diffusemHtt levels in striatal neu-
rons and extended their survival (Tsvetkov et al., 2010). Tubastatin A, an
inhibitor of the α-tubulin deacetylase HDAC6, was recently shown to
promote neuronal autophagic flux and reduce diffuse mHtt levels in
striatal neurons (Guedes-Dias et al., 2015). Encouragingly, HDAC6 inhi-
bition in an Alzheimer's diseasemousemodel facilitated the autophagic
degradation of amyloid-β and hyperphosphorylated tau, ameliorating
behavioral and cognitive deficits (Zhang et al., 2014). Further studies
will be required to assess the impact of these pharmacological strategies
in mouse models of HD, and how they affect mitochondrial dynamics
and quality control in vivo.6. Concluding remarks
Impaired mitochondrial dynamics and quality control pathways
seem to be emerging as common themes in a number of major neu-
rodegenerative diseases, leading to disturbed mitochondrial bioen-
ergetics and cell death in affected neuronal populations. The
literature reviewed here suggests that mHtt may impair neuronal
mitochondrial dynamics and quality control by several mechanisms.
Mitochondrial biogenesis may be decreased through reduced PGC-
1α expression, coupled with impaired protein import attributed to
mHtt interaction with TIM23. Reduced expression of fusion proteins
and increased expression/activity of fission-associated Drp1 are as-
sociated with excessive mitochondrial fission in the HD striatum.
Striatal neurons seem particularly vulnerable to trafficking impair-
ment by diffuse mHtt, which may disrupt trafficking complexes
such as the normal Htt-HAP1 association involved in retrograde
autophagosomal transport. Together with impaired cargo loading
by disturbed interactions with autophagic receptors, disturbed
transport may compromise the efficient autophagic degradation of
mHtt and mitochondria. These cumulative effects of mHtt on mito-
chondrial dynamics are predictably detrimental to mitochondrial
bioenergetics and quality control, and are likely to impact neuronal
homeostasis, given the high-energy requirements, postmitotic na-
ture, and polarized morphology of the neuron.
Pharmacological strategies that modulate mitochondrial function
have been showing promising results in several HDmodels. Approaches
to upregulate the PGC-1α pathway (e.g. PPAR agonists) were neuropro-
tective in cellular andmousemodels of HD (Johri et al., 2013), andphar-
macological inhibition of mitochondrial fission with P110 prevented
striatal neuronal loss and reduced mortality of R6/2 HD mice (Guo
et al., 2013). Lysine deacetylases (a.k.a. histone deacetylases;
HDACs) may also constitute viable targets for the modulation of mi-
tochondrial function (Guedes-Dias and Oliveira, 2013). Significantly,
pharmacological pan-inhibition of HDACs improved mitochondrial
calcium handling in striatal neurons expressing mHtt (Oliveira
et al., 2006), while selective inhibition of the α-tubulin deacetylase
HDAC6 promoted mitochondrial motility and fusion, and also in-
creased autophagic flux and mHtt clearance in striatal neurons
(Guedes-Dias et al., 2015).
Why mHtt expression is particularly damaging to striatal MSNs
remains incompletely understood, but increased susceptibility to im-
paired mitochondrial dynamics and quality control may be an impor-
tant piece of the HD pathogenic puzzle. Pharmacological approaches
capable of rescuing impaired mitochondrial dynamics and quality con-
trol are thus likely to hold therapeutic potential to reduce the vulnera-
bility of striatal MSNs in HD.
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